1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H2 2020, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.
Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 5, 4, 2, 5, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
- The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionBenign Prostatic Hyperplasia - Overview
Benign Prostatic Hyperplasia - Therapeutics Development
Benign Prostatic Hyperplasia - Therapeutics Assessment
Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
Benign Prostatic Hyperplasia - Drug Profiles
Benign Prostatic Hyperplasia - Dormant Projects
Benign Prostatic Hyperplasia - Discontinued Products
Benign Prostatic Hyperplasia - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Benign Prostatic Hyperplasia, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Aiviva BioPharma Inc, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Aphios Corp, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Aquestive Therapeutics Inc, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by ASKA Pharmaceutical Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Chengdu Dikang Pharmaceuticals Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by DongKoo Bio & Pharma Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Everon Biosciences Inc, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by GemVax & KAEL Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Huons Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Kolmar Pharma Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Kwang Dong Pharmaceutical Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corp, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio Inc, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by ValiRx Plc, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by Veru Inc, H2 2020
- Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H2 2020
- Benign Prostatic Hyperplasia - Dormant Projects, H2 2020
- Benign Prostatic Hyperplasia - Dormant Projects, H2 2020 (Contd..1), H2 2020
- Benign Prostatic Hyperplasia - Dormant Projects, H2 2020 (Contd..2), H2 2020
- Benign Prostatic Hyperplasia - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Benign Prostatic Hyperplasia, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aiviva BioPharma Inc
- Aphios Corp
- Aquestive Therapeutics Inc
- ASKA Pharmaceutical Co Ltd
- BCWorld Pharm Co Ltd
- Boryung Pharmaceutical Co Ltd
- Chengdu Dikang Pharmaceuticals Co Ltd
- Chong Kun Dang Pharmaceutical Corp
- Curadis GmbH
- DongKoo Bio & Pharma Co Ltd
- Dongkook Pharmaceutical Co Ltd
- Everon Biosciences Inc
- GemVax & KAEL Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Health Ever Bio-Tech Co Ltd
- Huons Co Ltd
- Jeil Pharmaceutical Co Ltd
- Kolmar Pharma Co Ltd
- Kwang Dong Pharmaceutical Co Ltd
- Mezzion Pharma Co Ltd
- Nymox Pharmaceutical Corp
- Ono Pharmaceutical Co Ltd
- Sophiris Bio Inc
- ValiRx Plc
- Veru Inc
- XuanZhu Pharma Co Ltd
